局部进展期前列腺癌的治疗策略

张大宏

doi:10.13201/j.issn.1001-1420.2015.03.001

局部进展期前列腺癌的治疗策略

张大宏^,

- 浙江省人民医院泌尿外科(杭州, 310014)

详细信息

通讯作者: 张大宏,E-mail:zhangdahong88@126.com

中图分类号: R737.25

收稿日期: 2014-12-28

Treatment strategy for locally advanced prostate cancer

ZHANG Dahong^,

- Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou, 310014, China

More Information

Corresponding author: ZHANG Dahong, E-mail: zhangdahong88@126.com

Received Date: 28 December 2014

摘要

摘要: 随着诊疗技术的进步,局部进展期前列腺癌(locally advanced prostate cancer, LAPC)患者的标准治疗模式目前仍处于探索当中。选择根治性手术(达芬奇机器人辅助)、放疗、内分泌治疗、局部治疗等诸多方法中的两种或两种以上方法联合的多模式治疗方法近年来均取得了不同进展,在肿瘤控制率、患者生存期上各有特色,同时对并发症的控制、对生活质量的影响亦有改善。本文就LAPC的诊治现状作一述评。
- 前列腺肿瘤 /
- 局部进展期 /
- 治疗
Abstract: With advances in medical technology, the standard treatment modalities in patients with locally advanced prostate cancer is under the station of exploring yet, chooseing two or more treatment methods such as radical surgery (Da Vinci robot-assisted),radiotherapy, endocrine therapy, topical treatment or combined multi-mode treatment methods have made different progress in recent years. It has their own characteristics in the tumor control rate and survival time of patients, while the complication was controlled and the impact on quality of life also was improved.
- prostate cancer /
- locally advanced /
- treatment

HTML全文

参考文献(19)

[1]	Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer[J]. J Clin, 2014, 64: 9-29.
[2]	那彦群, 叶章群, 孙颖浩, 等主编. 中国泌尿外科疾病诊断治疗指南[M]. 北京:人民卫生出版社,2014:.
[3]	Mohler J L, Kantoff P W, Armstrong A J, et al. Prostate cance, version 2, 2014[J]. J Natl Compr Canc Netw, 2014, 12(5): 686-718.
[4]	Augustin H, Sun M, Isbarn H, et al. Decision curve analysis to compare 3 versions of Partin Tables to predict final pathologic stage[J]. Urol Oncol, 2012, 30(4): 396-401.
[5]	Isbarn H, Huland H, Graefen M. Results of radical prostatectomy in newly diagnosed prostate cancer-long-term survival rates in locally advanced and high risk cancers[J]. Dtsch Arztebl Int, 2013, 110(29-30): 497-503.
[6]	Luigi M, Elisabetta N, Vittorio B, et al. Radical prostatectomy in high-risk prostate cancer: incidence of specimen-confined disease (pT₂-pT_3aN₀R₀) and outcomes[J]. Urologia, 2014, 81(2): 125-132.
[7]	Joniau S G, Van Baelen A A, Hsu C Y, et al. Complications and functional results of surgery for locally advanced prostate cancer[J]. Adv Urol, 2012, 2012: 706309.
[8]	Abdollah F,Gandaglia G,Suardi N,et al.More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer[J].Eur Urol,2014 May 29.pii: S0302-2838(14)00421-7.
[9]	Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial[J]. JAMA, 2006, 296(19): 2329-2335.
[10]	Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of arandomised controlled trial (EORTC trial 22911)[J]. Lancet, 2012, 380(9858): 2018-2027.
[11]	Wiegel T, Bottke D, Steiner U , et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specificantigen: ARO 96-02/AUO AP 09/95[J]. J Clin Oncol, 2009, 27(18): 2924-2930.
[12]	Silberstein J L, Poon S A, Sjoberg D D, et al. Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer[J]. BJU Int, 2014 Feb 19. doi: 10.1111/bju.12676.
[13]	Spahn M, Briganti A, Capitanio U, et al. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease[J]. J Urol, 2012, 188(1): 84-90.
[14]	Lilleby W, Stensvold A, Dahl A A. Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life[J]. J Prostate, 2013, 73(10): 1038-1047. 15 Luo H C, Cheng L P, Cheng H H, et al. Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation[J]. Med Oncol, 2014, 31(6): 991.
[16]	Ishiyama H, Satoh T, Kitano M, et al. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up[J]. J Radiat Res, 2014, 55(3): 509-517.
[17]	吴浩明, 吕军, 胡卫列, 等. 经直肠穿刺¹²⁵I粒子植入联合内分泌治疗局部晚期前列腺癌的临床疗效[J]. 中华男科学杂志, 2013, 19(7): 617-621.
[18]	John F W, Christopher J D, Christopher W, et al. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry[J]. BJU Int, 2014, 113: 714-718.
[19]	Uchida T, Tomonaga T, Kim H, et al. Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer[J]. J Urol, 2015, 193(1): 103-110.
[20]	Pastore A L, Palleschi G, Silvestri L, et al. Prospective randomized study of radiofrequency versus ultrasound scalpels on functional outcomes of laparoscopic radical prostatectomy[J]. J Endourol, 2013, 27(8): 989-993.